Format

Send to:

Choose Destination
See comment in PubMed Commons below
Circulation. 2014 Sep 30;130(14):1146-57. doi: 10.1161/CIRCULATIONAHA.114.009985. Epub 2014 Aug 1.

Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.

Author information

  • 1From Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (D.J.C., R.L.O., E.A.M., K.W., H.L., K.C.); Erasmus University Medical Center, Rotterdam, The Netherlands (R.L.O., A.P.K., P.W.S.); Harvard School of Public Health, Boston, MA (D.P.); Institut Jacques Cartier, Massy, France (M.-C.M.); Boston Scientific, Natick, MA (K.D.D.); and Herzzentrum Universität Leipzig, Leipzig, Germany (F.W.M.). dcohen@saint-lukes.org.
  • 2From Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (D.J.C., R.L.O., E.A.M., K.W., H.L., K.C.); Erasmus University Medical Center, Rotterdam, The Netherlands (R.L.O., A.P.K., P.W.S.); Harvard School of Public Health, Boston, MA (D.P.); Institut Jacques Cartier, Massy, France (M.-C.M.); Boston Scientific, Natick, MA (K.D.D.); and Herzzentrum Universität Leipzig, Leipzig, Germany (F.W.M.).

Abstract

BACKGROUND:

The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated that in patients with 3-vessel or left main coronary artery disease, coronary artery bypass graft surgery (CABG) was associated with a lower rate of cardiovascular death, myocardial infarction, stroke, or repeat revascularization compared with percutaneous coronary revascularization with drug-eluting stents (DES-PCI)). The long-term cost-effectiveness of these strategies is unknown.

METHODS AND RESULTS:

Between 2005 and 2007, 1800 patients with left main or 3-vessel coronary artery disease were randomized to CABG (n=897) or DES-PCI (n=903). Costs were assessed from a US perspective, and health state utilities were evaluated with the EuroQOL questionnaire. A patient-level microsimulation model based on the 5-year in-trial data was used to extrapolate costs, life expectancy, and quality-adjusted life expectancy over a lifetime horizon. Although initial procedural costs were $3415 per patient lower with CABG, total hospitalization costs were $10 036 per patient higher. Over the next 5 years, follow-up costs were higher with DES-PCI as a result of more frequent hospitalizations, revascularization procedures, and higher medication costs. Over a lifetime horizon, CABG remained more costly than DES-PCI, but the incremental cost-effectiveness ratio was favorable ($16 537 per quality-adjusted life-year gained) and remained <$20 000 per quality-adjusted life-year in most bootstrap replicates. Results were consistent across a wide range of assumptions about the long-term effect of CABG versus DES-PCI on events and costs. In patients with left main disease or a SYNTAX score ≤22, however, DES-PCI was economically dominant compared with CABG, although these findings were less certain.

CONCLUSIONS:

For most patients with 3-vessel or left main coronary artery disease, CABG is a clinically and economically attractive revascularization strategy compared with DES-PCI. However, among patients with less complex disease, DES-PCI may be preferred on both clinical and economic grounds.

CLINICAL TRIAL REGISTRATION URL:

www.clinicaltrials.gov. Unique identifier: NCT00114972.

© 2014 American Heart Association, Inc.

KEYWORDS:

coronary artery bypass; cost-benefit analysis; drug-eluting stents; percutaneous coronary intervention; randomized, controlled trials as topic

PMID:
25085960
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk